Loading...
SLXN
XNAS
Market cap34kUSD
Nov 20, Last price  
1.31USD
1D
-12.67%
1Q
-86.15%
IPO
-100.00%
Name

Biomotion Sciences

Chart & performance

D1W1MN
XNAS:SLXN chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
187.89%
Shs. 5Y
-68.00%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-12m
L-27.56%
-195,860-755,218-3,215,000-4,942,000-16,443,000-11,912,000
CFO
-11m
L+28.86%
-75,000-1,407,236-3,335,000-4,529,000-8,396,000-10,819,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

Key people

Mirit Hadar
Chief Financial Officer · since 2024
Mitchell Shirvan
Chief Scientific and Development Officer · since 2022
Chairman of the Board, Chief Executive Officer · since 2024
Dror Abramov
Independent Director · since 2024
Ruth Alon
Independent Director
Independent Director · since 2024
Independent Director · since 2024
Shlomo Noy
Independent Director · since 2024
Amnon Peled
Independent Director · since 2024
IPO date
Feb 17, 2021
Domiciled in
US
Incorporated in
KY

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT